Kiminori Kimura Selected Research

ICG 001

6/2022	Safety, tolerability, and anti-fibrotic efficacy of the CBP/β-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study.
9/2020	Anti-tumor Activity of the Small Molecule Inhibitor PRI-724 Against β-Catenin-activated Hepatocellular Carcinoma.
4/2019	Programmed cell death ligand 1 (PD-L1) blockade attenuates metastatic colon cancer growth in cAMP-response element-binding protein (CREB)-binding protein (CBP)/β-catenin inhibitor-treated livers.
10/2018	Wnt/β-Catenin Signaling as a Potential Target for the Treatment of Liver Cirrhosis Using Antifibrotic Drugs.
9/2017	Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial.
1/2017	Selective inhibitor of Wnt/β-catenin/CBP signaling ameliorates hepatitis C virus-induced liver fibrosis in mouse model.
11/2015	Inhibition of Cyclic Adenosine Monophosphate (cAMP)-response Element-binding Protein (CREB)-binding Protein (CBP)/β-Catenin Reduces Liver Fibrosis in Mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kiminori Kimura Research Topics

Disease

12	Infections 01/2021 - 11/2002
10	Liver Cirrhosis (Hepatic Cirrhosis) 06/2022 - 10/2006
9	Neoplasms (Cancer) 09/2020 - 06/2007
8	Fibrosis (Cirrhosis) 06/2022 - 10/2006
6	Hepatocellular Carcinoma (Hepatoma) 09/2020 - 10/2009
6	Chronic Hepatitis (Chronic Active Hepatitis) 01/2016 - 11/2002
5	Inflammation (Inflammations) 01/2016 - 11/2004
5	Liver Diseases (Liver Disease) 06/2015 - 11/2004
5	Chronic Hepatitis C 10/2012 - 12/2005
3	Hepatitis C 06/2022 - 01/2012
3	Hepatitis 01/2021 - 01/2009
2	Fatty Liver 01/2018 - 01/2012
2	Hepatitis B 01/2014 - 12/2005
2	Autoimmune Diseases (Autoimmune Disease) 10/2009 - 11/2004
1	End Stage Liver Disease 06/2022
1	Colonic Neoplasms (Colon Cancer) 04/2019
1	Neoplasm Metastasis (Metastasis) 04/2019
1	Adenocarcinoma of Lung 01/2019
1	Chronic Hepatitis B 05/2018
1	Non-alcoholic Fatty Liver Disease 01/2018
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 10/2014
1	Pyoderma Gangrenosum 02/2014
1	Disease Progression 01/2014
1	Persistent Infection 10/2012
1	Neuromyelitis Optica (Devic's Disease) 11/2010
1	Agammaglobulinemia (Hypogammaglobulinemia) 11/2010
1	Lymphopenia (Lymphocytopenia) 11/2010
1	Pathologic Processes 01/2010
1	Polymyositis 10/2009
1	Prion Diseases (Transmissible Spongiform Encephalopathies) 07/2007
1	Scrapie 07/2007
1	Massive Hepatic Necrosis 07/2007
1	Liver Failure 06/2007
1	Acute Liver Failure (Fulminant Hepatic Failure) 06/2007

Drug/Important Bio-Agent (IBA)

8	CateninsIBA 06/2022 - 11/2015
7	ICG 001IBA 06/2022 - 11/2015
6	CytokinesIBA 11/2019 - 11/2004
6	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2018 - 11/2004
5	Proteins (Proteins, Gene)FDA Link 01/2019 - 01/2010
5	Antiviral Agents (Antivirals)IBA 02/2014 - 11/2002
4	Cyclic AMP Response Element-Binding Protein (Cyclic AMP-Responsive DNA-Binding Protein)IBA 04/2019 - 11/2015
3	InterferonsIBA 10/2009 - 12/2005
3	AntigensIBA 06/2008 - 07/2007
2	CollagenIBA 06/2022 - 01/2018
2	CREB-Binding ProteinIBA 04/2019 - 11/2015
2	entecavir FDA Link 05/2018 - 01/2014
2	Carrier Proteins (Binding Protein)IBA 01/2018 - 11/2015
2	Adenosine Monophosphate (AMP)IBA 01/2018 - 11/2015
2	GalactosamineIBA 01/2018 - 06/2007
2	Phosphotransferases (Kinase)IBA 01/2018 - 01/2017
2	Biomarkers (Surrogate Marker)IBA 01/2017 - 06/2015
2	Interleukin-6 (Interleukin 6)IBA 01/2016 - 01/2012
2	VaccinesIBA 01/2016 - 10/2012
2	Interleukin-18 (Interleukin 18)IBA 03/2011 - 11/2002
2	Ribavirin (Virazole)FDA LinkGeneric 10/2009 - 12/2005
2	Dimethylnitrosamine (Nitrosodimethylamine)IBA 12/2007 - 10/2006
2	NF-kappa B (NF-kB)IBA 07/2007 - 11/2004
2	Interferon-gamma (Interferon, gamma)IBA 10/2006 - 03/2006
1	Serum AlbuminIBA 06/2022
1	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2021
1	C.I. direct red 80IBA 01/2020
1	Hepatitis B Vaccines (Hepatitis B Vaccine)IBA 01/2020
1	Bone Morphogenetic Protein 4IBA 11/2019
1	AntibodiesIBA 04/2019
1	Immune Checkpoint InhibitorsIBA 04/2019
1	LigandsIBA 04/2019
1	emerinIBA 01/2019
1	Sorafenib (BAY 43-9006)FDA Link 01/2017
1	Coloring Agents (Dyes)IBA 01/2017
1	SilverIBA 01/2017
1	Hydroxyproline (4 Hydroxyproline)IBA 01/2017
1	Matrix Metalloproteinases (MMPs)IBA 11/2015
1	Carbon Tetrachloride (Tetrachloromethane)IBA 11/2015
1	EnzymesIBA 06/2015
1	ImmunosorbentsIBA 06/2015
1	acarboxyprothrombin (PIVKA)IBA 06/2015
1	ChromatinIBA 10/2014
1	DNA (Deoxyribonucleic Acid)IBA 01/2014
1	AcidsIBA 01/2012
1	InterleukinsIBA 01/2012
1	Poly CIBA 01/2012
1	GlycogenIBA 01/2012
1	Therapeutic UsesIBA 01/2012
1	Pharmaceutical PreparationsIBA 11/2010
1	Interferon-alpha (Interferon Alfa)IBA 10/2009
1	NucleosidesIBA 10/2009
1	Messenger RNA (mRNA)IBA 06/2008
1	Peptides (Polypeptides)IBA 05/2008
1	EpitopesIBA 05/2008
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 12/2007
1	Prion ProteinsIBA 07/2007
1	CASP8 and FADD-Like Apoptosis Regulating Protein (FLIP-S)IBA 06/2007

Therapy/Procedure

13	Therapeutics 01/2021 - 11/2004
2	Hematopoietic Stem Cell Transplantation 05/2018 - 01/2014
2	Drug Therapy (Chemotherapy) 09/2017 - 06/2013
1	Intravenous Administration 06/2022
1	Ligation 11/2015
1	Injections 01/2009
1	Intraperitoneal Injections 10/2006
1	Intravenous Injections 03/2006